1. A 52-year-old woman with major depressive disorder has been stable on vortioxetine 20 mg once daily for 14 months. She is seen by a second physician for obsessive-compulsive symptoms who adds fluoxetine 20 mg daily without consulting her psychiatrist. Three weeks later she presents to her psychiatrist complaining of persistent nausea, headache, and dizziness that began shortly after the new prescription. Her vortioxetine and fluoxetine are both confirmed as current medications. Which of the following is the most appropriate immediate management?
A) Discontinue vortioxetine entirely and continue fluoxetine as the sole antidepressant, since both drugs act through serotonergic mechanisms and the combination is redundant as well as toxic.
B) Discontinue fluoxetine and add a non-serotonergic augmenting agent for the OCD symptoms, because the only safe management is complete removal of the interacting drug rather than dose adjustment of vortioxetine.
C) Reduce vortioxetine to a maximum of 10 mg daily while continuing fluoxetine, because fluoxetine is a potent CYP2D6 inhibitor and CYP2D6 is vortioxetine's primary metabolic enzyme; the combination approximately doubles vortioxetine plasma concentrations, producing the dose-related adverse effects she is experiencing.
D) Increase the vortioxetine dose to 25 mg to overcome competitive displacement of vortioxetine from CYP2D6 binding sites by fluoxetine, restoring adequate drug levels at the enzyme level while maintaining therapeutic effect.
E) Add ondansetron 4 mg as needed to manage the nausea symptomatically while continuing both drugs unchanged, since the nausea is self-limiting and the interaction does not require dose modification of either agent.
ANSWER: C
Rationale:
Fluoxetine is a potent inhibitor of CYP2D6, which is the primary enzyme responsible for vortioxetine metabolism. When fluoxetine is added to a stable vortioxetine regimen, it substantially impairs vortioxetine's metabolic clearance, functionally converting the patient's phenotype from an extensive metabolizer to a poor metabolizer and approximately doubling vortioxetine plasma concentrations. The resulting elevated drug exposure produces dose-related adverse effects — nausea, headache, and dizziness — consistent with vortioxetine at supratherapeutic concentrations. The prescribing information for vortioxetine specifies a dose reduction to a maximum of 10 mg daily when potent CYP2D6 inhibitors including fluoxetine, paroxetine, or bupropion are coadministered. This adjustment preserves both the antidepressant and the OCD augmentation strategy while eliminating the adverse effect burden by returning vortioxetine exposure to the intended therapeutic range.
Option A: Option A is incorrect because discontinuing vortioxetine entirely is unnecessarily disruptive to a 14-month stable antidepressant regimen; a dose reduction to 10 mg maintains therapeutic effect and resolves the interaction without abandoning an effective treatment.
Option B: Option B is incorrect because complete removal of the interacting drug may be necessary in some interaction scenarios but is not required here; the prescribing information specifically provides dose reduction guidance for this combination, and dose adjustment is the preferred management over full discontinuation of a recently added augmenting agent that may be clinically indicated for OCD.
Option D: Option D is incorrect because the interaction causes elevated vortioxetine levels, not reduced levels; increasing the dose in the context of CYP2D6 inhibition would further elevate already-supratherapeutic plasma concentrations and worsen the adverse effects rather than restoring normal drug exposure.
Option E: Option E is incorrect because the adverse effects reflect genuinely elevated vortioxetine plasma concentrations requiring dose adjustment, not a transient or self-limiting phenomenon; managing symptoms without addressing the underlying pharmacokinetic interaction allows the elevated exposure to persist and does not constitute appropriate management of a clinically significant drug-drug interaction.
2. A 29-year-old man with major depressive disorder and comorbid insomnia is prescribed trazodone 150 mg at bedtime. He has no cardiac history and normal liver function. Before he leaves the clinic, which of the following adverse effects requires specific informed consent discussion that is unique to male patients at the time of prescribing trazodone?
A) Priapism — a prolonged, painful erection unrelated to sexual stimulation occurring in approximately 1 in 6,000 to 1 in 8,000 male patients, caused by alpha-1 adrenergic blockade in the penile vasculature; the patient must be instructed to seek emergency evaluation immediately if an erection persists beyond two to four hours, as delayed treatment can result in permanent erectile dysfunction.
B) Testicular atrophy from suppression of luteinizing hormone secretion, which occurs in approximately 5% to 8% of male patients on trazodone within the first three months of treatment and requires testosterone monitoring at baseline and every six months during ongoing therapy.
C) Retrograde ejaculation caused by alpha-1 adrenergic blockade at the bladder neck, which affects the majority of male patients on trazodone at doses above 100 mg and requires dose reduction to 50 mg if it occurs to preserve fertility in patients of reproductive age.
D) Gynecomastia from trazodone-mediated prolactin elevation through dopamine D2 receptor blockade in the pituitary, which develops gradually over six to twelve months and requires discontinuation if breast tissue enlargement is detected on examination.
E) Permanent azoospermia from direct serotonergic toxicity to Sertoli cells in the testes, which has been reported at an estimated rate of 1 in 2,000 male patients on doses above 100 mg and requires baseline semen analysis before initiating trazodone in patients who desire future fertility.
ANSWER: A
Rationale:
Priapism is the adverse effect requiring specific informed consent in male patients at trazodone initiation. It occurs in approximately 1 in 6,000 to 1 in 8,000 male patients and is caused by alpha-1 adrenergic receptor blockade in the vasculature of the corpora cavernosa, which impairs the sympathetically mediated vasoconstriction that normally produces detumescence. The result is a prolonged, painful, non-sexual erection that constitutes a urological emergency. If untreated, ischemic priapism lasting more than four to six hours produces irreversible hypoxic injury to corporal smooth muscle and can result in permanent erectile dysfunction. Patients must be explicitly told at initiation to seek emergency care immediately — not to wait until the next available appointment — if an erection persists beyond two to four hours. This counseling is mandatory because delayed presentation is the primary cause of permanent injury, and patients who are not warned may not recognize the urgency.
Option B: Option B is incorrect because trazodone does not suppress LH secretion or cause testicular atrophy; this mechanism is associated with opioids and anabolic steroids, not with trazodone's pharmacological profile, and the monitoring protocol described does not exist for trazodone.
Option C: Option C is incorrect because while alpha-1 adrenergic blockade can in principle affect bladder neck function, retrograde ejaculation is not a commonly documented or clinically significant adverse effect of trazodone, and the claim that it affects the majority of male patients at doses above 100 mg is pharmacologically unsupported and substantially overstates the incidence.
Option D: Option D is incorrect because trazodone does not block dopamine D2 receptors and does not cause clinically significant prolactin elevation; D2 blockade-mediated hyperprolactinemia and gynecomastia are adverse effects of antipsychotics, not trazodone, which lacks significant dopaminergic activity.
Option E: Option E is incorrect because trazodone does not cause serotonergic toxicity to Sertoli cells or azoospermia; this adverse effect does not appear in trazodone's pharmacological literature or prescribing information, and the specific incidence figure cited fabricates a spermatotoxic effect that has no established pharmacological basis.
3. A 44-year-old woman in the United Kingdom is six weeks into treatment with agomelatine 25 mg at bedtime for major depressive disorder. She has no pre-existing liver disease and does not drink alcohol. At a routine follow-up visit, liver function tests ordered per the monitoring protocol show AST 142 U/L (reference range <35 U/L, representing approximately 4 times the upper limit of normal) and ALT 118 U/L (reference range <35 U/L, approximately 3.4 times the upper limit of normal). She is asymptomatic. What is the correct next step?
A) Continue agomelatine at the current dose and recheck liver function tests in four weeks; asymptomatic enzyme elevations below five times the upper limit of normal are within the acceptable monitoring threshold and do not require any change in management at this stage.
B) Reduce the agomelatine dose to 12.5 mg at bedtime and recheck liver function tests in two weeks; dose reduction is the recommended first response to transaminase elevations between three and five times the upper limit of normal before considering full discontinuation.
C) Add ursodeoxycholic acid to protect the liver while continuing agomelatine at the current dose; hepatoprotective agents are the recommended co-prescription when agomelatine-associated enzyme elevations are detected in asymptomatic patients.
D) Switch agomelatine to an SSRI immediately and refer the patient to hepatology for liver biopsy to determine whether the enzyme elevations represent drug-induced liver injury or incidental hepatic pathology requiring separate treatment.
E) Discontinue agomelatine immediately; the prescribing guidelines require discontinuation of agomelatine when transaminase levels exceed three times the upper limit of normal, regardless of whether the patient is symptomatic, because this threshold identifies patients at risk for progression to more severe hepatic injury.
ANSWER: E
Rationale:
The EMA prescribing guidelines for agomelatine specify that any elevation of transaminases above three times the upper limit of normal requires immediate discontinuation, regardless of whether the patient is symptomatic. This patient's AST is approximately four times the upper limit of normal — above the three-times threshold — making immediate discontinuation mandatory. The monitoring protocol established for agomelatine at 6 weeks, 12 weeks, and 24 weeks exists precisely to detect these elevations before they progress to symptomatic hepatitis or fulminant hepatic failure. The fact that the patient is asymptomatic does not change the requirement: the discontinuation threshold is defined by the laboratory value, not by the presence of symptoms, because clinical symptoms of hepatic injury — jaundice, right upper quadrant pain, dark urine, fatigue — may not appear until liver injury is already severe. Prompt discontinuation at the laboratory threshold is designed to prevent symptomatic progression.
Option A: Option A is incorrect because the threshold for mandatory discontinuation is three times the upper limit of normal, and this patient is at approximately four times that level; continuing and rechecking in four weeks while the transaminases are already above the action threshold violates the prescribing guideline and risks progressive hepatic injury during the observation period.
Option B: Option B is incorrect because dose reduction is not the recommended response to transaminase elevations above three times the upper limit of normal in the agomelatine prescribing guidelines; the guideline specifies discontinuation at this threshold, not dose reduction, and there is no established dose-reduction protocol for managing agomelatine-associated liver enzyme elevations.
Option C: Option C is incorrect because ursodeoxycholic acid as a hepatoprotective co-prescription while continuing agomelatine is not a recognized or guideline-supported management strategy; the correct action is discontinuation, and continuing a hepatotoxic drug with a hepatoprotective agent does not constitute appropriate management of drug-induced liver enzyme elevation above the action threshold.
Option D: Option D is incorrect because liver biopsy is not the appropriate immediate next step; the correct first action is discontinuation of the offending agent, after which further hepatic workup can be considered if the enzyme elevation does not resolve or if an alternative cause is suspected; referring to hepatology while the drug is continued is not guideline-compliant.
4. A 67-year-old man with major depressive disorder and chronic insomnia was previously dependent on temazepam, which was tapered and discontinued two years ago after a prolonged struggle. His psychiatrist proposes trazodone 75 mg at bedtime to manage residual insomnia as part of his depression treatment. The patient asks whether trazodone will cause the same kind of dependence and tolerance he experienced with temazepam. Which of the following responses is pharmacologically accurate?
A) Trazodone carries the same dependence risk as temazepam because both drugs produce sedation through central nervous system depression; any drug that produces sedation by acting in the brain will produce physiological dependence with continued use, and the patient should expect a similar taper requirement when discontinuing trazodone.
B) Trazodone at hypnotic doses does not produce physical dependence, tolerance, or a withdrawal syndrome; it is not a scheduled controlled substance, and unlike benzodiazepines it does not produce its sedative effect through GABA-A receptor potentiation — it acts through histamine H1 antagonism and alpha-1 adrenergic blockade, mechanisms that do not produce the physiological adaptation underlying benzodiazepine dependence.
C) Trazodone does not produce dependence in the short term, but tolerance to its hypnotic effect develops reliably after approximately four to six weeks of nightly use, at which point the dose must be increased progressively to maintain sleep benefit, making long-term use impractical without ongoing dose escalation.
D) Trazodone is not scheduled and does not produce benzodiazepine-type dependence, but it does produce serotonergic dependence through SERT inhibition at hypnotic doses; patients stopping trazodone abruptly after long-term use may experience serotonin discontinuation syndrome with electric shock sensations, dizziness, and flu-like symptoms comparable in severity to SSRI discontinuation.
E) Trazodone is safer than temazepam but still carries a low dependence risk requiring scheduling as a DEA Schedule V controlled substance; while physical dependence is less severe than with Schedule IV benzodiazepines, patients with a prior benzodiazepine dependence history have a significantly elevated risk of trazodone misuse and should be monitored with urine drug screens.
ANSWER: B
Rationale:
Trazodone at hypnotic doses (50 to 150 mg at bedtime) does not produce physical dependence, tolerance, or a clinically significant withdrawal syndrome, and it is not a scheduled controlled substance under the DEA. Its sedative mechanism at these doses is potent histamine H1 receptor antagonism combined with alpha-1 adrenergic blockade — neither of which produces the GABA-A receptor upregulation and neuroadaptation that underlies benzodiazepine physical dependence. Benzodiazepines such as temazepam enhance GABA-A receptor chloride conductance; chronic exposure produces compensatory receptor downregulation and reduced GABA sensitivity, which manifests as tolerance, dose escalation, and a withdrawal syndrome on discontinuation. Trazodone's pharmacodynamic mechanisms do not drive this type of adaptation, making it a safe hypnotic choice specifically for patients with prior benzodiazepine dependence, in whom scheduled hypnotics carry significant relapse and misuse risk.
Option A: Option A is incorrect because sedation through different pharmacodynamic mechanisms does not confer equivalent dependence risk; the dependence liability of benzodiazepines arises specifically from GABA-A receptor modulation, which trazodone does not produce, and equating all sedating drugs in terms of dependence potential ignores the receptor-level mechanisms that determine physiological adaptation.
Option C: Option C is incorrect because clinically significant tolerance to trazodone's hypnotic effect developing reliably after four to six weeks of nightly use with required dose escalation is not established in the pharmacological literature; trazodone is used as a long-term hypnotic in clinical practice without the progressive dose escalation that characterizes benzodiazepine and z-drug tolerance.
Option D: Option D is incorrect because trazodone at hypnotic doses does not produce clinically meaningful SERT occupancy sufficient to cause serotonergic discontinuation syndrome comparable to SSRI discontinuation; the doses used for insomnia are too low for the transporter-mediated neuroadaptation that drives discontinuation symptoms, as established in prior pharmacodynamic analysis.
Option E: Option E is incorrect because trazodone is not a DEA scheduled controlled substance at any schedule; it has no scheduling requirement, and describing it as Schedule V misrepresents its regulatory classification — a particularly important correction for a patient with prior dependence who may be reassured or concerned by scheduling status.
5. A 38-year-old man with treatment-refractory major depressive disorder has been taking generic nefazodone for four months following failure of four prior antidepressant trials. He presents to his primary care physician reporting a two-week history of progressive fatigue, yellow discoloration of his eyes and skin, dark urine, and right upper quadrant discomfort. He drinks no alcohol. Liver function tests show AST 1,840 U/L, ALT 2,210 U/L, total bilirubin 5.4 mg/dL. What is the most important immediate step?
A) Reduce nefazodone to half the current dose and add N-acetylcysteine intravenously to replenish hepatic glutathione stores; this two-pronged approach addresses both the ongoing drug exposure and the oxidative stress mechanism of nefazodone hepatotoxicity.
B) Continue nefazodone at the current dose and refer urgently to gastroenterology for upper endoscopy to rule out biliary obstruction as a cause of the jaundice before attributing the liver injury to the medication.
C) Switch nefazodone to trazodone immediately, since trazodone is the other SARI-class drug and shares nefazodone's antidepressant mechanism without the hepatotoxicity risk; the antidepressant treatment can be maintained without interruption.
D) Discontinue nefazodone immediately and arrange urgent hepatic evaluation; the clinical presentation — jaundice, right upper quadrant pain, dark urine, and markedly elevated transaminases — represents symptomatic hepatotoxicity, which is the specific adverse event described in nefazodone's black-box warning and requires immediate drug withdrawal regardless of the antidepressant consequences.
E) Hold nefazodone for two weeks and rechallenge at a lower dose once liver function tests normalize; rechallenge with careful dose titration is the recommended approach in the prescribing information for patients who develop mild-to-moderate hepatic enzyme elevations without jaundice.
ANSWER: D
Rationale:
This patient presents with symptomatic hepatotoxicity — jaundice, right upper quadrant pain, dark urine, and transaminases elevated to more than 50 times the upper limit of normal — while taking nefazodone. This is the clinical presentation that nefazodone's black-box warning describes: life-threatening hepatic injury including cases of fulminant hepatic failure and death. The immediate and non-negotiable management step is discontinuation of nefazodone, followed by urgent hepatic evaluation to assess severity, monitor for progression to fulminant hepatic failure, and determine whether hepatology or transplant consultation is required. No dose reduction, rechallenge, or continuation strategy is appropriate when symptomatic hepatotoxicity with jaundice and markedly elevated transaminases is present. Antidepressant management must be addressed after the hepatic emergency is stabilized, not concurrently with the acute liver injury.
Option A: Option A is incorrect because dose reduction is not an acceptable response to symptomatic hepatotoxicity with jaundice and transaminases at this level; nefazodone must be completely discontinued, and while N-acetylcysteine has a role in acetaminophen hepatotoxicity, it is not the established treatment for nefazodone's mitochondrial complex I inhibition mechanism.
Option B: Option B is incorrect because biliary obstruction workup is not the priority in a patient with a known hepatotoxic drug, a presentation consistent with drug-induced liver injury, and transaminase levels in the thousands — the drug must be stopped immediately, and further workup can proceed after discontinuation rather than while the offending agent continues.
Option C: Option C is incorrect because switching to trazodone maintains a serotonergic antidepressant but does not address the acute hepatic emergency; furthermore, switching antidepressants mid-crisis diverts clinical attention from the immediate priority of stopping nefazodone and evaluating hepatic severity.
Option E: Option E is incorrect because rechallenge with a drug that has caused symptomatic hepatotoxicity with jaundice is absolutely contraindicated; nefazodone's prescribing information does not support rechallenge after jaundice has developed, and rechallenging a patient who has survived a severe hepatic episode with the causative drug would represent a serious prescribing error.
6. A 55-year-old woman with major depressive disorder was started on vilazodone 40 mg once daily eight weeks ago. She reports only partial improvement in mood — better than before but not reaching her prior baseline. She is adherent and takes her medication every morning before her coffee, before eating breakfast. She has no interacting medications. Her physician considers increasing the dose to 60 mg. Before doing so, which pharmacokinetic factor should be identified and corrected?
A) Vilazodone's absorption is reduced by morning cortisol elevation, which activates hepatic CYP3A4 and increases first-pass metabolism; she should switch to evening dosing to take advantage of lower cortisol and reduced enzyme activity during the overnight period.
B) Vilazodone undergoes enterohepatic recirculation that is disrupted by fasting; the bile required for recirculation is only secreted in response to dietary fat, so taking the drug before breakfast eliminates the recirculation phase that normally sustains plasma concentrations throughout the morning.
C) Vilazodone's oral bioavailability is approximately 72% when taken with food but falls to approximately 47% in the fasted state; taking the drug consistently before eating means she has been receiving approximately 35% less drug exposure than intended at the prescribed dose, which most likely explains her partial response and should be corrected by instructing her to take vilazodone with food before considering a dose increase.
D) Vilazodone requires alkaline pH in the small intestine for optimal dissolution, and fasting increases gastric acid secretion; the low pH environment during fasting degrades vilazodone before it can be absorbed, and she should be prescribed a proton pump inhibitor to normalize gastric pH and restore adequate bioavailability.
E) Morning administration on an empty stomach accelerates gastric emptying, causing vilazodone to reach the small intestine too rapidly for adequate dissolution; she should take the medication with a small amount of water and remain upright for 30 minutes after administration to slow intestinal transit and allow adequate time for drug dissolution before absorption.
ANSWER: C
Rationale:
Vilazodone has an oral bioavailability of approximately 72% when taken with food and approximately 47% when taken in the fasted state — a clinically significant difference of approximately 35 percentage points. The prescribing information classifies food coadministration as a mandatory requirement, not a recommendation, specifically because this bioavailability reduction is large enough to result in subtherapeutic drug exposure at the prescribed dose. This patient has been taking her medication consistently on an empty stomach before breakfast, meaning she has likely been receiving substantially less drug exposure than the dose was intended to deliver. Correcting the administration error by instructing her to take vilazodone with a meal is the appropriate first step before any dose increase is considered; a dose increase without correcting the food administration error would result in an unnecessary escalation, since adequate plasma concentrations may be achieved simply by taking the drug correctly.
Option A: Option A is incorrect because morning cortisol elevation activating hepatic CYP3A4 is not an established pharmacokinetic mechanism for vilazodone's food effect; the bioavailability difference is related to overall absorption conditions in the fed versus fasted state, not to a time-of-day enzyme induction pattern.
Option B: Option B is incorrect because vilazodone does not undergo clinically relevant enterohepatic recirculation; the food effect is an absorption phenomenon, not a recirculation phenomenon, and bile-dependent recirculation is not part of vilazodone's established pharmacokinetic profile.
Option D: Option D is incorrect because vilazodone's food effect is not explained by acid-mediated degradation; the drug is not chemically unstable in gastric acid, and proton pump inhibitor therapy is not an established or indicated approach to managing vilazodone's food-dependent bioavailability.
Option E: Option E is incorrect because the mechanism described — rapid gastric emptying causing inadequate dissolution time — is not the established pharmacokinetic explanation for vilazodone's food requirement, and the management recommendation of remaining upright for 30 minutes is not a guideline-supported intervention for this drug's bioavailability concern.
7. A 35-year-old woman presents with a two-year history of major depressive disorder and comorbid generalized anxiety disorder (GAD). She completed a 12-week trial of escitalopram 20 mg with good antidepressant response but persistent, significant anxiety symptoms throughout. She is reluctant to add a second medication and asks whether a single agent could address both conditions. She has no hepatic disease, eats regular meals, and has no insomnia. Which agent from this module offers the most pharmacologically rational single-agent strategy for her presentation?
A) Vilazodone, because it combines SERT inhibition with 5-HT1A partial agonism; the 5-HT1A partial agonist activity acts on postsynaptic hippocampal 5-HT1A receptors in a manner analogous to buspirone's established anxiolytic mechanism, potentially providing antidepressant and anxiolytic activity from a single agent that addresses both conditions mechanistically.
B) Vortioxetine, because its 5-HT3 antagonism at amygdalar receptors specifically attenuates the hypervigilance and threat-detection bias that characterizes GAD, and its multimodal serotonergic profile offers both antidepressant and directly targeted anxiolytic activity that vilazodone's mechanism does not provide.
C) Trazodone, because adding it at 50 mg three times daily provides daytime anxiolytic sedation through H1 antagonism that directly addresses the hyperarousal component of GAD while its SERT inhibition maintains antidepressant coverage, combining both effects in a non-scheduled drug.
D) Agomelatine, because the circadian dysregulation that underlies GAD responds to MT1/MT2 agonism, which normalizes the hypothalamic-pituitary-adrenal axis hyperactivity that drives persistent anxiety in patients with comorbid MDD and GAD; this mechanism is distinct from SERT inhibition and avoids the sexual adverse effects of escitalopram.
E) Nefazodone, because its potent 5-HT2A antagonism prevents the postsynaptic serotonergic overstimulation that drives residual anxiety in patients who achieved mood response on SSRIs, and switching to nefazodone would eliminate both the residual anxiety and the need for a second agent by addressing the mechanism escitalopram left untreated.
ANSWER: A
Rationale:
Vilazodone is the most pharmacologically rational single-agent choice for this patient. Its combination of SERT inhibition and 5-HT1A partial agonism directly addresses both conditions through mechanistically complementary pathways: the SERT inhibition provides antidepressant activity comparable to escitalopram, while the 5-HT1A partial agonism at postsynaptic hippocampal receptors provides anxiolytic activity through the same receptor mechanism that underlies buspirone's efficacy in GAD. Vilazodone's 5-HT1A affinity is approximately equivalent to buspirone's, and buspirone is a guideline-supported treatment for GAD. Because this patient has regular meals and no insomnia, vilazodone's food requirement and absence of sedating properties are well-matched to her profile. The mechanistic rationale for vilazodone in comorbid MDD and GAD is the strongest among the five agents in this module.
Option B: Option B is incorrect because vortioxetine's clinical niche in this module relates primarily to cognitive dysfunction in MDD rather than comorbid GAD; while its 5-HT3 antagonism has anxiolytic properties in preclinical models, vortioxetine is not established as superior to vilazodone in patients whose primary residual complaint is anxiety, and the specific amygdalar 5-HT3 mechanism described overstates the clinical evidence base.
Option C: Option C is incorrect because trazodone at anxiolytic daytime doses produces unacceptable sedation that would be functionally disabling for a working adult; its clinical use is as a bedtime hypnotic, not as a thrice-daily anxiolytic, and its antidepressant doses of 300 to 600 mg daily are limited by orthostatic hypotension and sedation.
Option D: Option D is incorrect because agomelatine is not FDA-approved in the United States and is not available in standard US formularies; furthermore, the specific HPA axis normalization mechanism described for GAD overstates the established evidence base for agomelatine's anxiolytic effects, and its mandatory liver function test (LFT) monitoring adds burden without indication in this patient.
Option E: Option E is incorrect because nefazodone's hepatotoxicity risk makes it inappropriate as a first switch option for a patient with MDD and GAD who has not exhausted safer alternatives; its risk-benefit profile is reserved for truly refractory depression after multiple adequate trials, not for residual anxiety after a single SSRI trial with good mood response.
8. A 48-year-old man with treatment-refractory major depressive disorder is maintained on generic nefazodone after failing five prior antidepressant trials. He is seen by his cardiologist for hyperlipidemia; his LDL is 168 mg/dL and the cardiologist proposes starting simvastatin 40 mg nightly to meet his cardiovascular risk target. The patient brings the new prescription to his psychiatrist before filling it. What is the correct response?
A) Approve the simvastatin prescription as written; nefazodone's hepatotoxicity risk is already being monitored with liver function tests, and the combination with simvastatin requires no additional precaution because nefazodone's interaction profile primarily affects serotonergic drugs rather than statins.
B) Approve simvastatin at a reduced dose of 10 mg nightly with monthly creatine kinase monitoring; the CYP3A4 interaction increases simvastatin exposure but the risk of myopathy is manageable at 10 mg without requiring a statin switch.
C) Approve simvastatin but instruct the patient to take it in the morning and nefazodone at bedtime, since separating the dosing times by 12 hours reduces the CYP3A4 interaction sufficiently to prevent clinically significant simvastatin accumulation.
D) Discontinue nefazodone and switch to a different antidepressant before starting simvastatin, because nefazodone's black-box hepatotoxicity warning and its CYP3A4 inhibition together make any statin combination unacceptably risky and require psychiatric drug replacement first.
E) Do not approve simvastatin as prescribed; contact the cardiologist to explain that nefazodone is a potent CYP3A4 inhibitor that markedly increases simvastatin plasma concentrations and raises the risk of rhabdomyolysis, and request that simvastatin be substituted with pravastatin or rosuvastatin — statins not dependent on CYP3A4 metabolism — before the prescription is filled.
ANSWER: E
Rationale:
Nefazodone is a potent CYP3A4 inhibitor, and simvastatin is primarily metabolized by CYP3A4. Coadministration would markedly increase simvastatin plasma concentrations — potentially several-fold — by severely impairing both intestinal and hepatic first-pass and systemic simvastatin metabolism. Because statin-induced myopathy and rhabdomyolysis are concentration-dependent adverse effects, this combination carries a clinically unacceptable risk of skeletal muscle toxicity, and the combination is listed as a contraindication in nefazodone's prescribing information. The correct response is to contact the cardiologist before the prescription is filled, explain the interaction, and request substitution with a statin that does not depend on CYP3A4 for its primary metabolism. Pravastatin undergoes minimal CYP metabolism and is eliminated through non-CYP pathways; rosuvastatin has minor CYP2C9 dependency with no significant CYP3A4 involvement. Either is appropriate for this patient's lipid management without the rhabdomyolysis risk.
Option A: Option A is incorrect because nefazodone's CYP3A4 inhibition does produce a clinically significant interaction with simvastatin — this is not restricted to serotonergic drug interactions; nefazodone's inhibitory profile at CYP3A4 is broad and includes statins, benzodiazepines, and other substrates regardless of their pharmacological mechanism.
Option B: Option B is incorrect because a 10 mg dose reduction does not safely manage the magnitude of CYP3A4 inhibition produced by nefazodone; the interaction can produce several-fold increases in simvastatin exposure, and a dose of 10 mg with monitoring is not an established or guideline-supported approach to this contraindicated combination — statin substitution is required.
Option C: Option C is incorrect because separating the administration times by 12 hours does not resolve a CYP3A4 enzyme inhibition interaction; CYP3A4 inhibition by nefazodone is present throughout the dosing interval as long as nefazodone plasma concentrations remain elevated, and the inhibitory effect is not limited to the brief period immediately after nefazodone dosing.
Option D: Option D is incorrect because discontinuing nefazodone to switch antidepressants is a much more disruptive intervention than substituting simvastatin with a safer statin; a patient who has failed five antidepressant trials and is currently stable on nefazodone should not have that treatment disrupted for a statin interaction when the interaction can be resolved by changing the statin rather than the antidepressant.
9. A 61-year-old woman with major depressive disorder has been on sertraline 150 mg for eight months with good mood response — her PHQ-9 score has improved from 18 to 6. However, she continues to report significant difficulty with word retrieval, slowed thinking, poor concentration, and reduced executive function that are interfering with her work as a project manager. She asks whether a medication change could address these cognitive symptoms. She has no hepatic disease, no insomnia, and eats regular meals. Which of the following represents the most pharmacologically rational next step?
A) Add donepezil 5 mg daily to sertraline; acetylcholinesterase inhibition raises synaptic acetylcholine in cortical and hippocampal circuits and directly addresses the cholinergic deficit that underlies cognitive impairment in major depressive disorder in older adults.
B) Switch to vortioxetine; its 5-HT3 and 5-HT7 receptor antagonism disinhibits norepinephrine, dopamine, and acetylcholine release in prefrontal and hippocampal circuits, providing a pharmacological basis for cognitive improvement that clinical trial data have shown to be at least partially independent of mood response — making it the most evidence-supported choice for residual cognitive dysfunction after antidepressant treatment.
C) Switch to agomelatine; its MT1/MT2 melatonin receptor agonism normalizes the circadian rhythm disruption that drives cognitive impairment in aging adults with MDD, and its 5-HT2C antagonism disinhibits prefrontal dopaminergic tone, providing a targeted mechanism for cognitive improvement in this age group.
D) Add methylphenidate 5 mg twice daily to sertraline; stimulant augmentation is the most evidence-based approach to antidepressant-resistant cognitive symptoms in adults over 60 and directly raises prefrontal dopaminergic and noradrenergic tone through reuptake inhibition at both the DAT and NET.
E) Continue sertraline and refer for formal neuropsychological testing; cognitive symptoms in a 61-year-old with depression may represent early neurodegenerative disease rather than a pharmacologically addressable deficit, and treatment modification should be deferred until the etiology of the cognitive impairment is established.
ANSWER: B
Rationale:
Vortioxetine is the most pharmacologically rational choice for this patient's primary complaint of residual cognitive dysfunction after an adequate antidepressant response. Its multimodal mechanism — specifically 5-HT3 and 5-HT7 receptor antagonism removing inhibitory serotonergic tone from GABAergic interneurons — disinhibits the release of norepinephrine, dopamine, and acetylcholine in prefrontal and hippocampal circuits, providing a mechanistic basis for cognitive improvement beyond what SERT inhibition alone achieves. The FOCUS trial demonstrated statistically significant improvements in processing speed, attention, and executive function in patients with MDD who had inadequate prior antidepressant response, and these improvements were present even after controlling for changes in depression severity — establishing that the cognitive benefit is at least partially pharmacologically direct rather than purely secondary to mood improvement. Switching from sertraline to vortioxetine maintains serotonergic antidepressant coverage while adding the pro-cognitive receptor-level mechanisms.
Option A: Option A is incorrect because donepezil is approved for Alzheimer's disease dementia, not for the cognitive effects of MDD; adding an acetylcholinesterase inhibitor to an antidepressant without evidence of neurodegenerative disease is not a guideline-supported approach to antidepressant-related cognitive dysfunction in a patient whose cognitive symptoms began with the depressive episode.
Option C: Option C is incorrect because agomelatine is not FDA-approved in the United States and is not available in standard US formularies; while its 5-HT2C-mediated disinhibition of PFC dopaminergic tone is pharmacologically relevant, it is clinically unavailable for routine prescribing in the US and has not established superiority over vortioxetine for cognitive outcomes in MDD.
Option D: Option D is incorrect because stimulant augmentation with methylphenidate for antidepressant-resistant cognitive symptoms in adults over 60 is not established as first-line or evidence-based in this context; it carries risks of cardiovascular effects, anxiety exacerbation, and potential for misuse, and is not supported as a standard approach before trying an antidepressant with a direct pro-cognitive mechanism such as vortioxetine.
Option E: Option E is incorrect because deferring treatment modification pending formal neuropsychological testing unnecessarily delays addressing a pharmacologically tractable symptom; while neurodegenerative disease is a differential consideration, cognitive symptoms that emerged with the depressive episode, in a patient with no other features of neurodegeneration, are appropriately addressed with an antidepressant modification trial before referral for neuropsychological workup.
10. A 40-year-old man transfers his psychiatric care to a US academic medical center from a hospital in the Netherlands, where he had been treated for major depressive disorder. His medication list includes agomelatine 50 mg at bedtime, which he has taken for approximately five months. The receiving intern reviews his records and notes that no liver function tests are documented anywhere in the transferred chart. The patient feels well and has no complaints. What is the most appropriate immediate action?
A) Discontinue agomelatine immediately pending a full hepatic workup, since the absence of documented liver function monitoring represents a protocol violation that mandates drug withdrawal until the patient's hepatic status is formally established and the safety record is reviewed.
B) Continue agomelatine without interruption and order liver function tests at the next scheduled follow-up in three months, since the patient is asymptomatic and five months of uneventful treatment without any reported symptoms provides reasonable indirect evidence that no significant hepatotoxicity has occurred.
C) Contact the prior treating physician in the Netherlands to obtain the missing monitoring records before taking any clinical action; no management decision should be made without first confirming whether the monitoring was performed and not transferred rather than genuinely not performed.
D) Order liver function tests immediately and establish the ongoing monitoring schedule going forward; the EMA guidelines require testing at baseline, 6 weeks, 12 weeks, and 24 weeks — regardless of whether the prior tests were obtained, current hepatic status must be established before continuing the drug, and monitoring must be maintained prospectively from this point.
E) Switch agomelatine to an SSRI immediately, since agomelatine is not FDA-approved and cannot be legally continued in US clinical practice; the transition to a US-approved antidepressant is required before the patient can receive ongoing psychiatric care at a US institution.
ANSWER: D
Rationale:
The immediate clinical priority is to establish the patient's current hepatic status and to ensure that ongoing monitoring is in place going forward. The EMA guidelines require liver function testing at baseline, 6 weeks, 12 weeks, and 24 weeks after initiating agomelatine, with periodic testing thereafter. At five months of treatment, the patient should have had at least four sets of liver function tests; the absence of documented tests is clinically concerning, regardless of whether they were performed and not transferred or genuinely not performed. Current hepatic status must be established before continuing the drug: ordering liver function tests now identifies any ongoing elevation that would require discontinuation, and establishes a baseline for prospective monitoring going forward. This approach is clinically sound regardless of what the prior records show.
Option A: Option A is incorrect because immediate discontinuation is not required in an asymptomatic patient simply because monitoring documentation is missing; the appropriate response is to check current hepatic status, and if liver function tests are normal, to continue agomelatine with prospective monitoring in place.
Option B: Option B is incorrect because continuing without immediate liver function testing — and deferring testing by three months — is not appropriate for a patient on agomelatine with no documented monitoring; the drug's hepatotoxicity risk requires that current hepatic status be established promptly, and three months of additional unmonitored exposure before checking is not consistent with the monitoring protocol.
Option C: Option C is incorrect because obtaining records from the prior physician is a reasonable secondary step but should not delay the immediate clinical action of checking current liver function tests; a patient's hepatic status needs to be assessed now, independent of whether historical tests were obtained, and waiting for overseas record retrieval before acting is not appropriate clinical management.
Option E: Option E is incorrect because agomelatine's lack of FDA approval does not make it illegal to continue in US clinical practice; physicians may prescribe non-FDA-approved drugs obtained through appropriate channels, and the clinical priority is safe ongoing management, not immediate drug substitution based on regulatory status alone.
11. A 33-year-old woman with recurrent major depressive disorder has had two prior antidepressant failures. She discontinued sertraline after four months due to intolerable sexual dysfunction despite good mood response. She then tried vilazodone, which was discontinued after three weeks due to severe diarrhea that did not improve despite taking it with food and completing the titration schedule. She works as a nurse on rotating day and night shifts and frequently cannot predict meal timing. She has no hepatic disease and no insomnia. Her psychiatrist proposes a third trial. Which agent from this module is most appropriate, and which pharmacological features make it the correct choice for this specific patient?
A) Agomelatine, because its MT1/MT2 mechanism avoids all monoamine transporter activity, eliminating the serotonergic mechanism responsible for sexual dysfunction; its lack of SERT activity means it will not reproduce either of her prior adverse effects, and its circadian mechanism will benefit her rotating shift schedule.
B) Trazodone at antidepressant doses, because its 5-HT2A antagonism specifically blocks the postsynaptic serotonin receptors responsible for SSRI-induced sexual dysfunction; it does not cause diarrhea and does not require food coadministration, making it suitable for her irregular meal schedule.
C) Vortioxetine, because its oral bioavailability of approximately 75% is unaffected by food — directly addressing the meal-timing constraint created by her rotating shift schedule — and clinical trial data demonstrate rates of sexual dysfunction comparable to placebo, directly addressing the adverse effect that ended her sertraline trial; it acts through a pharmacological mechanism distinct from vilazodone's enteric 5-HT1A partial agonism that caused her diarrhea.
D) Nefazodone, because it lacks the alpha-1 adrenergic activity responsible for trazodone's sedation and orthostatic hypotension, does not require food coadministration, and its 5-HT2A antagonism avoids the serotonergic sexual dysfunction mechanism; for a patient who has failed two prior agents, nefazodone's risk-benefit profile becomes acceptable.
E) A second trial of vilazodone at 20 mg as the maximum dose without escalating to 40 mg, because her diarrhea was likely a dose-dependent effect of reaching the 40 mg target and a lower ceiling dose would maintain antidepressant efficacy while eliminating the GI adverse effect that caused discontinuation.
ANSWER: C
Rationale:
Vortioxetine addresses all three of this patient's key clinical constraints simultaneously. First, its oral bioavailability of approximately 75% is unaffected by food intake, directly resolving the meal-timing problem created by her rotating shift schedule; unlike vilazodone — whose bioavailability drops from 72% to 47% in the fasted state and requires mandatory food coadministration — vortioxetine can be taken at any time regardless of meal timing without compromising drug exposure. Second, clinical trial data using prospective sexual function assessment instruments demonstrate that vortioxetine produces rates of sexual dysfunction comparable to placebo, making it the agent with the strongest evidence for a favorable sexual profile in this module; this directly addresses the adverse effect that caused her sertraline discontinuation. Third, vortioxetine's gastrointestinal adverse effect profile is nausea rather than diarrhea, and nausea typically attenuates within one to two weeks; it does not share vilazodone's dual enteric mechanism (SERT plus 5-HT1A partial agonism on enteric neurons) that drove her severe diarrhea.
Option A: Option A is incorrect because agomelatine is not FDA-approved in the United States and is not available in standard US formularies; while its lack of transporter activity would avoid sexual dysfunction and its circadian mechanism is relevant for shift workers, it cannot be routinely prescribed in US practice, and the mandatory LFT (liver function test) monitoring schedule adds burden without indication.
Option B: Option B is incorrect because trazodone at antidepressant doses of 300 to 600 mg daily produces dose-limiting sedation and orthostatic hypotension that are particularly problematic for a nurse working rotating shifts; trazodone at these doses is rarely used as a stand-alone antidepressant precisely because of these tolerability issues, and the sedation risk during shift work is clinically unacceptable.
Option D: Option D is incorrect because nefazodone's black-box hepatotoxicity risk and potent CYP3A4 inhibitory interaction profile are not justified after only two prior antidepressant failures; nefazodone's risk-benefit threshold is reserved for patients with truly refractory depression after multiple adequate trials with safer alternatives, and a 33-year-old woman with two failures — one for a side effect, one for a GI adverse effect — does not meet that threshold when vortioxetine remains untried.
Option E: Option E is incorrect because vilazodone's diarrhea is driven by both SERT inhibition and enteric 5-HT1A partial agonism at the gut level, not exclusively by the 40 mg dose; the patient completed the titration schedule and took the drug with food, meaning the standard tolerability measures were applied, and a lower maximum dose does not reliably eliminate the enteric 5-HT1A-mediated diarrhea mechanism that distinguishes vilazodone from conventional SSRIs.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.